Alicia Collins is the head of Cell Therapy Global Patient Operations at Bristol Myers Squibb, and part of the team that commercially launched the company’s first two cell therapy products. Alicia has 25 years of experience in the pharmaceutical and biotech industry at Merck, Genentech, and BMS in domestic and international roles. Her experience encompasses supply chain, both internal and external manufacturing, and materials management. Alicia has a B.S. in Integrated Science & Technology with a double-concentration in biotechnology and environmental science from James Madison University.